Article info
PDFA difficult case
Refractory CIDP with chronic lymphocytic leukaemia responding to chemoimmunotherapy
- Correspondence to Dr Chinar Osman, Wessex Neurological Centre, Southampton University Hospitals NHS Trust, Southampton, Southampton, UK; chinar.osman{at}uhs.nhs.uk
Citation
Refractory CIDP with chronic lymphocytic leukaemia responding to chemoimmunotherapy
Publication history
- Accepted December 14, 2020
- First published December 29, 2020.
Online issue publication
March 16, 2021
Article Versions
- Previous version (29 December 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Chronic inflammatory demyelinating polyneuropathy caused by hepatocellular carcinoma
- Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP
- Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features
- Application of the 2021 EAN/PNS criteria for chronic inflammatory demyelinating polyneuropathy
- Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment
- Treatment of CIDP
- Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy
- Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin
- Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study
- Anti-MAG/SGPG associated neuropathy does not commonly cause distal nerve temporal dispersion